Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
09 nov. 2020 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
26 oct. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab reduced time-to-flare and increased sustained remission in Phase 2 giant cell arteritis clinical trial -- Primary and secondary efficacy endpoints achieved statistical significance...
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
06 oct. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
15 sept. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
12 nov. 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in...
Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology
12 juin 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Preclinical data support rationale for targeting GM-CSF in GCA – - Mavrilimumab shows biological effect on genes relevant to GCA pathophysiology in ex vivo cultures of GCA arteries – HAMILTON,...
Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
30 mai 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 30, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
03 janv. 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various...